Respiratory Syncytial Virus: Recognizing and Mitigating Risk in Vulnerable Adults

Release Date: Tuesday, September 27, 2022
Expiration Date: Wednesday, September 27, 2023

EDUCATIONAL OVERVIEW
Respiratory Syncytial Virus (RSV) is associated with a substantial burden among vulnerable adults, including the elderly, immunocompromised, and those with chronic medical conditions. Though RSV is typically a seasonal infection, the impact of COVID-19 precautions may have contributed to a recent rise in cases, particularly in the southern states. Healthcare providers should have a thorough understanding of the burden of RSV and identify patients at risk of severe infection to offer education on prevention and awareness. This activity discusses the incidence and burden of RSV in adults, patient risk factors for severe infection, and current and emerging approaches in prevention.

LEARNING OBJECTIVES
Upon completing this activity, participants will be able to:

Discuss the burden of respiratory syncytial virus (RSV) infection in adults and list patient risk factors for severe infection and hospitalization
Describe diagnostic approaches to differentiate RSV from other respiratory viral infections in adults
Identify current and emerging approaches to prevent RSV in vulnerable adults

TARGET AUDIENCE
This activity meets the needs of primary care providers including internists, family physicians, osteopathic physicians, physician assistants, and nurse practitioners who are involved in the evaluation and management of adults at risk of serious RSV infection.

FACULTY

	Stefan Gravenstein, MD, MPH Professor of Medicine Director, Division of Geriatrics & Palliative Care Brown University Providence, RI

EDUCATIONAL FORMAT

The Online Presentation, based on a live series at primary care societies, aims to increase understanding and awareness of PCPs in recognizing the burden and risk of RSV among their vulnerable patients. The presentation focuses on a number of issues that are pertinent to PCPs in the management of RSV, including:

Identifying patient risk factors for severe infection
Changes in RSV epidemiology during COVID
Recognizing potential serious complications of infection
Differentiating RSV from other viral infections
Who and how to test for RSV infection
Educating patients about preventive approaches
Emerging options in prophylaxis

Accreditation and Credit Designation Statement

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurse Practitioners
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit™ as this is an ACCME accredited program and its accreditation is recognized by Nurse Practitioner boards.

For questions regarding the accreditation of this activity, please contact us at info@jointsponsor.com

Method of Participation and Instruction for Credit

Review the entire CME information including target audience, learning objectives, and disclosures.
Review the activity in its entirety.
Complete the Online Post Test, Evaluation, and Credit Application form
Please note that to receive credit you must achieve a score of at least 80%.
Certificate of Credit will be emailed to you within 4 weeks.

Disclosure of Financial Relationships with Ineligible Companies
Center for Independent Healthcare Education and Vemco MedEd fully comply with the Standards for Integrity and Independence in Accredited Continuing Education in development of CME/CPE activities. We require the full disclosure of financial relationships with ineligible companies from all individuals in a position to influence the content of a certified activity, in any amount occurring within the past 24 months. All relevant financial relationship is identified by the provider and mitigated to prevent inserting commercial bias into content. All identified relevant financial relationships are disclosed to the learners prior to the activity. The faculty is further required to disclose discussion of off-label uses in their presentations.

Disclosures
Dr. Stefan Gravenstein reported the following relevant financial relationships with ineligible companies:

Consulting: Sanofi, Merck & Co., Inc., Pfizer Inc., Novavax, VaxArt, Janssen, Moderna, GSK, Reviral
Speakers Bureau: Seqirus, Sanofi, Janssen
Research Support: Seqirus, Sanofi, Pfizer Inc.
Advisory Board: Janssen

All relevant financial relationships have been mitigated.
Dr. Gravenstein does not discuss off-label uses of any products.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Fee
There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

System Check
Please e-mail any questions or concerns to info@vemcomeded.com.

Privacy Policy
http://www.vemcomeded.com/privacy.asp

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support
This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

START ACTIVITY
By clicking below, I acknowledge that I have read the entire CME information.